CTI BioPharma Corp.
CTI BioPharma Corp. (CTIC) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CTIC · as of Jun 9, 2026
Key Statistics
Explore CTI BioPharma Corp. Data
ctic stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 19 · Buy rate: 68.4%
The CTIC analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $10.40, representing +14.35% upside from the current price of $9.10.
Competitors & Peers
ctic competitorsCTIC
CBIO
CINC
EQRX
ETHZ
GRCLStock Performance
Full HistoryAbout CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key…
what is cti biopharma corp. · ctic stock overview · cti biopharma corp. company profile · who is cti biopharma corp. ceo · ctic NASDAQ · cti biopharma corp. headquarters · cti biopharma corp. business segments
About Stock Overview & Key Data
CTI BioPharma Corp. (CTIC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 21, 1997. As of the latest trading session, CTIC stock price is $9.10, with a market capitalization of $1.2B. The stock has returned +50.33% over the past 12 months and +55.20% year-to-date.
According to 19 Wall Street analysts, the consensus rating for CTI BioPharma Corp. stock is Buy, with an average 12-month price target of $10.40. In fiscal year 2022, CTI BioPharma Corp. reported revenue of $53.9M and net income of -$91.0M. For detailed data — including CTI BioPharma Corp. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, CTI BioPharma Corp. (CTIC) stock price is $9.10. The stock is traded on NASDAQ under the ticker symbol CTIC. The 52-week range is $4.01 – $9.10.